logo

Aimmune Therapeutics Inc. (AIMT)



Trade AIMT now with
  Date
  Headline
10/15/2018 8:05:22 AM Aimmune Reports Initiation Of Phase 2 Study With Regeneron, Sanofi Of AR101 With Adjunctive Dupilumab In Peanut-Allergic
8/9/2018 9:05:53 AM Wedbush Is Raising Aimmune Therapeutics Inc. (AIMT) FY19 Estimate To -2.72 From -2.73
8/9/2018 9:05:38 AM Wedbush Is Lowering Aimmune Therapeutics Inc. (AIMT) FY18 Estimate To -3.35 From -3.26
8/9/2018 9:05:18 AM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Outperform With $72 Price Target
6/11/2018 4:01:53 PM Aimmune Therapeutics Appoints Dr. Jayson Dallas As CEO
5/30/2018 11:07:39 AM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Outperform With $72 Price Target
5/30/2018 6:04:54 AM Aimmune Therapeutics Says New Pan-European Study Showing Significant Psychosocial Burden Associated With Peanut Allergy
5/10/2018 10:43:00 AM Wedbush Is Lowering Aimmune Therapeutics Inc. (AIMT) FY19 Estimate To -2.73 From -2.63
5/10/2018 10:42:44 AM Wedbush Is Lowering Aimmune Therapeutics Inc. (AIMT) FY18 Estimate To -3.26 From -2.92
5/10/2018 10:42:30 AM Wedbush Is Lowering Aimmune Therapeutics Inc. (AIMT) Q4 18 Estimate To -0.77 From -0.74
5/10/2018 10:41:55 AM Wedbush Is Lowering Aimmune Therapeutics Inc. (AIMT) Q3 18 Estimate To -0.76 From -0.73
5/10/2018 10:40:56 AM Wedbush Is Lowering Aimmune Therapeutics Inc. (AIMT) Q2 18 Estimate To -0.81 From -0.73
5/10/2018 10:39:17 AM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Outperform With $72 Price Target
3/12/2018 8:09:56 AM Aimmune Therapeutics Q4 Net Loss $41.2 Mln Or $0.81 Per Share
3/6/2018 7:23:26 AM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Outperform With $72 Price Target
2/27/2018 8:26:49 AM RBC Capital Markets Is Raising Aimmune Therapeutics Inc. (AIMT) FY20 Rev. Estimate To 449.54 M From 397.82 M
2/27/2018 8:26:35 AM RBC Capital Markets Is Increasing Aimmune Therapeutics Inc. (AIMT) FY19 Rev. Estimate To 142.01 M From 126.00 M
2/27/2018 8:25:45 AM RBC Capital Markets Is Raising Aimmune Therapeutics Inc. (AIMT) FY20 Estimate To 2.69 From 2.29
2/27/2018 8:25:34 AM RBC Capital Markets Is Raising Aimmune Therapeutics Inc. (AIMT) FY19 Estimate To -1.35 From -1.86